Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | EPOR | P19235 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19034928 | 0.92 | GLP1R (0.55) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL19034958 | 0.92 | GLP1R (0.55) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL19034938 | 0.92 | GLP1R (0.55) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL19049678 | 0.92 | GLP1R (0.55) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL20653031 | 0.91 | GLP1R (0.66) | GLP1RNOD1FOLH1 | |
| SCHEMBL20652766 | 0.91 | GLP1R (0.54) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL20652822 | 0.91 | GLP1R (0.54) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL20652648 | 0.91 | GLP1R (0.54) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL20653022 | 0.91 | GLP1R (0.54) | GLP1RITGB3ITGA2BEPOREPHX2 | |
| SCHEMBL21099666 | 0.90 | GLP1R (0.65) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000923-A1 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-01-03 | — | — | US | disclosed |
| WO-2017109706-A1 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) | NOVARTIS AG (CH) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000923-A1 | METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) | HDGF, FABP1, GLS2 | GLP1R 105/4885ITGB3 4041/4885ITGA2B 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.